Quest Diagnostics Expands Oncology Testing Access Via Flatiron Health's OncoEMR MPI

MT Newswires Live07-08

Quest Diagnostics (DGX) has expanded access to its oncology testing for solid tumor cancers through Flatiron Health's electronic oncology medical record platform OncoEMR MPI, it said Wednesday.

The integration is expected to allow 4,700 clinicians within the Flatiron network of 1,600 cancer care locations in the US to quickly access Quest's services without leaving their existing workflow, the company said.

Certain providers are now able to order and receive results from Quest using the OncoEMR MPI as part of a pilot program, Quest said, adding that it plans to launch the full OncoEMR MPI integration to providers nationwide in H2.

Shares of Quest Diagnostics were down 0.7%.

Price: 210.12, Change: -1.41, Percent Change: -0.66

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment